Scleroderma (Systemic Sclerosis) – Landscape & Forecast – Disease Landscape & Forecast

Scleroderma, also known as systemic sclerosis (SSc), is a rare, progressive, and debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin thickening, and, often, painful digital ulcers. Mortality risks of pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), and renal crisis are high in SSc patients. Boehringer Ingelheim’s Ofev (nintedanib) and Roche / Genentech’s Actemra / RoActemra (tocilizumab) are two of the more-recent therapies specifically targeting the SScILD subpopulation. They have demonstrated the ability to slow the progressive loss of lung function. Other therapies are commonly prescribed off-label for overlapping symptoms. Although the SSc pipeline is large and diverse, most agents are in early development. Moreover, the development of SSc therapies has historically been associated with high failure rates, in part due to the heterogeneity of the patient population and the commensurate challenges with trial design.

Questions answered

  • How large is the diagnosed SSc population in the United States and EU5, and how will it change over the next 10 years?
  • What is the current treatment landscape in SSc?
  • What is the impact of newer-to-market therapies, and how will they change the treatment landscape over the next 10 years?
  • What do key opinion leaders view as the greatest unmet medical needs in the management of SSc?
  • What is the commercial potential of key emerging therapies? How will they fit into the SSc treatment landscape?

Content highlights

  • Geographies: United States and EU5.
  • Primary research: Six country-specific interviews with thought-leading SSc specialists supported by survey data collected for this study.
  • Epidemiology: Diagnosed prevalence of SSc by country, disease severity, and drug-treatment rates.
  • Forecast: Drug-level sales and patient share of key SSc therapies through 2032.
  • Emerging therapies: Phase 3: 1 drug; Phase 1 / 2: 9 drugs.

Product description

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports